Parenteral > General injections > unspecified:
250 mg in vial powder for injection (as sodium salt) ;
1 g in vial powder for injection (as sodium salt) ;
2 g in vial powder for injection (as sodium salt) (EML)
The Expert Committee noted that necrotizing fasciitis is a rare but severe skin and soft tissue infection that is associated with significant morbidity and mortality, especially in cases of delayed diagnosis and treatment.
The Committee noted the previous decision not to include empiric antibiotic treatment for severe skin and soft tissue infections, and to focus rather on mild, community-acquired infections. However, given the serious consequences of delayed treatment in necrotizing fasciitis, the Committee considered recommendations for empiric antibiotic therapy would be beneficial from both a clinical and public health perspective.
The Expert Committee reviewed the antibiotics proposed for listing for necrotizing fasciitis in the 2017 application and recommended expanding the indications for ceftriaxone, clindamycin, metronidazole, piperacillin + tazobactam and vancomycin on the EML and EMLc to include them as first-choice treatment options for treatment of necrotizing fasciitis as proposed in the application, including the addition of new intravenous formulations of ceftriaxone 2 g, clindamycin 600 mg and 900 mg, and vancomycin 500 mg and 1 g.